---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-088141"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:12:56.184961+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunome reports FY2025 net loss $212.4M; cash $653.5M; varegacestat NDA planned Q2 2026

## Summary
- Cash and equivalents $653.5M as of Dec 31, 2025; runway expected into 2028.
- Net loss of $212.4M for FY2025; R&D expenses $177.3M.
- Phase 3 RINGSIDE met primary endpoint: 84% reduction in risk of progression or death (HR=0.16, p<0.0001).
- NDA submission for varegacestat in desmoid tumors planned for Q2 2026.
- Three IND submissions for solid tumor ADCs (IM-1617, IM-1340, IM-1335) planned in 2026.

## SEC filing metadata
- accession: 0001193125-26-088141
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/0001193125-26-088141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-088141
- JSON: https://secwatch.observer/filing/0001193125-26-088141.json
- Plain text: https://secwatch.observer/filing/0001193125-26-088141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.